Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma.
Animals
Cancer Vaccines
/ administration & dosage
Cells, Cultured
Combined Modality Therapy
Dendritic Cells
/ immunology
Disease Models, Animal
Dog Diseases
/ diagnosis
Dogs
Doxorubicin
/ pharmacology
Female
Hemangiosarcoma
/ veterinary
Immunophenotyping
Immunotherapy
Male
Monte Carlo Method
Vaccination
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
23
11
2018
accepted:
16
12
2018
pubmed:
24
1
2019
medline:
7
7
2020
entrez:
24
1
2019
Statut:
ppublish
Résumé
Angiosarcoma is a deadly neoplasm of the vascular endothelium. Metastatic disease is often present at diagnosis, and 5-year survival is only 10-35%. Although there exist no immunocompetent mouse models of angiosarcoma with which to study immune-based approaches to therapy, angiosarcoma is a major killer of companion dogs, responsible for up to 2% of all canine deaths in some susceptible breeds or an estimated 120,000 per year in the US. The canine disease (HSA) often presents in the spleen as acute hemoabdomen secondary to splenic rupture. Even if life-saving splenectomy is performed, median overall survival (OS) is only 48 days, and 1-year survival is negligible. Here we report the analysis of a pilot phase I open-label trial of chemo-immunotherapy performed on consecutively presenting splenectomized canines with histologically verified HSA. Subjects received an abbreviated course of low-dose doxorubicin plus alpha interferon and an autologous dendritic cell-therapy reported to enhance durable CD8
Identifiants
pubmed: 30670791
doi: 10.1038/s41417-019-0080-3
pii: 10.1038/s41417-019-0080-3
pmc: PMC6760631
doi:
Substances chimiques
Cancer Vaccines
0
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
282-291Subventions
Organisme : NIAID NIH HHS
ID : R01 AI127387
Pays : United States
Références
Mendenhall WM, Mendenhall CM, Werning JW, Reith JD, Mendenhall NP. Cutaneous angiosarcoma. Am J Clin Oncol. 2006;29:524–8.
pubmed: 17023791
doi: 10.1097/01.coc.0000227544.01779.52
Ravi V, Patel S. Vascular sarcomas. Curr Oncol Rep. 2013;15:347–55.
pubmed: 23852636
doi: 10.1007/s11912-013-0328-2
Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010;11:983–91.
pubmed: 20537949
doi: 10.1016/S1470-2045(10)70023-1
Abraham JA, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007;14:1953–67.
pubmed: 17356953
doi: 10.1245/s10434-006-9335-y
Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11:241–7.
doi: 10.1097/00130404-200505000-00011
pubmed: 16053668
Post SM. Mouse models of sarcomas: critical tools in our understanding of the pathobiology. Clin Sarcoma Res. 2012;2:20.
pubmed: 23036318
pmcid: 3499229
doi: 10.1186/2045-3329-2-20
Rothweiler S, et al. Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model. Lab Invest. 2015;95:351–62.
pubmed: 25418579
doi: 10.1038/labinvest.2014.141
Alvarez FJ, Hosoya K, Lara-Garcia A, Kisseberth W, Couto G. VAC protocol for treatment of dogs with stage III hemangiosarcoma. J Am Anim Hosp Assoc. 2013;49:370–7.
pubmed: 24051260
doi: 10.5326/JAAHA-MS-5954
Lana S, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med. 2007;21:764–9.
pubmed: 17708397
doi: 10.1111/j.1939-1676.2007.tb03019.x
Sorenmo K, et al. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma. J Vet Intern Med. 2007;21:1347–54.
pubmed: 18196746
doi: 10.1111/j.1939-1676.2007.tb01958.x
Wendelburg KM, et al. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). J Am Vet Med Assoc. 2015;247:393–403.
pubmed: 26225611
doi: 10.2460/javma.247.4.393
Wood CA, et al. Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993). J Am Anim Hosp Assoc. 1998;34:417–21.
pubmed: 9728473
doi: 10.5326/15473317-34-5-417
Dillman R, et al. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas. Cancer Biother Radiopharm. 2004;19:581–8.
pubmed: 15650450
Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG. Dendritic cell-based immunotherapy: state of the art and beyond. Clin Cancer Res. 2016;22:1897–906.
pubmed: 27084743
doi: 10.1158/1078-0432.CCR-15-1399
Mackall CL, et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 2008;14:4850–8.
pubmed: 18676758
pmcid: 2497450
doi: 10.1158/1078-0432.CCR-07-4065
U’Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med. 2007;21:113–20.
pubmed: 17338158
doi: 10.1111/j.1939-1676.2007.tb02936.x
Decker WK, et al. Deficient T(H)-1 responses from TNF-alpha-matured and alpha-CD40-matured dendritic cells. J Immunother. 2008;31:157–65.
pubmed: 18481385
doi: 10.1097/CJI.0b013e31815eb0df
Decker WK, et al. Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens. Blood. 2009;113:4213–23.
pubmed: 19171878
pmcid: 2676083
doi: 10.1182/blood-2008-10-185470
Decker WK, et al. Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. Vaccine. 2006;24:3203–16.
pubmed: 16480795
doi: 10.1016/j.vaccine.2006.01.029
Halpert MM, et al. Dendritic cell-secreted cytotoxic T-lymphocyte-associated protein-4 regulates the T-cell response by downmodulating bystander surface B7. Stem Cells Dev. 2016;25:774–87.
pubmed: 26979751
pmcid: 4870609
doi: 10.1089/scd.2016.0009
V Konduri et al. Genetic adjuvantation of a cell-based therapeutic vaccine for amelioration of chagasic cardiomyopathy. Infect Immun 85, pii: e00127–17 (2017).
Konduri V, et al. Chemo-immunotherapy mediates durable cure of orthotopic Kras(G12D)/p53(−/−) pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5:e1213933.
pubmed: 27757308
pmcid: 5048769
doi: 10.1080/2162402X.2016.1213933
Liang D, Halpert MM, Konduri V, Decker WK. Stepping out of the cytosol: AIMp1/p43 potentiates the link between innate and adaptive immunity. Int Rev Immunol. 2015;34:367–81.
pubmed: 26325028
doi: 10.3109/08830185.2015.1077829
Liang D, et al. AIMp1 potentiates TH1 polarization and is critical for effective antitumor and antiviral immunity. Front Immunol. 2017;8:1801.
pubmed: 29379495
doi: 10.3389/fimmu.2017.01801
Decker WK, et al. Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models. Front Immunol. 2017;8:829.
pubmed: 28824608
pmcid: 5539135
doi: 10.3389/fimmu.2017.00829
Moore AS, Rassnick KM, Frimberger AE. Evaluation of clinical and histologic factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and adjuvant chemotherapy: 30 cases (2011-2014). J Am Vet Med Assoc. 2017;251:559–65.
pubmed: 28828962
doi: 10.2460/javma.251.5.559
Lee AW, et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine. 2002;20:A8–22.
pubmed: 12477423
doi: 10.1016/S0264-410X(02)00382-1
Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood. 2002;100:1354–61.
pubmed: 12149218
doi: 10.1182/blood-2001-11-0017
Hazenberg BP. Amyloidosis: a clinical overview. Rheum Dis Clin North Am. 2013;39:323–45.
pubmed: 23597967
doi: 10.1016/j.rdc.2013.02.012
Clifford CA, Mackin AJ, Henry CJ. Treatment of canine hemangiosarcoma: 2000 and beyond. J Vet Intern Med. 2000;14:479–85.
pubmed: 11012108
doi: 10.1111/j.1939-1676.2000.tb02262.x
Brown NO, Patnaik AK, MacEwen EG. Canine hemangiosarcoma: retrospective analysis of 104 cases. J Am Vet Med Assoc. 1985;186:56–58.
pubmed: 4038395
Finotello R, Stefanello D, Zini E, Marconato L. Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma. Vet Comp Oncol. 2017;15:25–35.
pubmed: 25623994
doi: 10.1111/vco.12139
Rai G, Mishra S, Suman S, Shukla Y. Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: a mechanistic insight. Phytomedicine. 2016;23:233–42.
pubmed: 26969377
doi: 10.1016/j.phymed.2015.12.020
Kim TH, et al. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta. 2014;1840:615–25.
pubmed: 24161697
doi: 10.1016/j.bbagen.2013.10.023
A Carlson et al. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines. Vet Comp Oncol. 2017;16:253–261.
pubmed: 29235249
pmcid: 5943135
doi: 10.1111/vco.12375
Vail DM, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res. 1995;1:1165–70.
pubmed: 9815908
De Silva NH, et al. Development of effective tumor immunotherapy using a novel dendritic cell-targeting Toll-like receptor ligand. PLoS ONE 2017;12:e0188738.
pubmed: 29190690
pmcid: 5708771
doi: 10.1371/journal.pone.0188738
Mito K, et al. IFN{gamma} markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models. Cancer Res. 2010;70:7093–101.
pubmed: 20823157
doi: 10.1158/0008-5472.CAN-10-0600
Gyorffy S, et al. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J Vet Intern Med. 2005;19:56–63.
pubmed: 15715049
Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol. 2008;103:776–87.
pubmed: 18076735
doi: 10.1111/j.1572-0241.2007.01669.x
Coles LS, Young RD. Supercentenarians and transthyretin amyloidosis: the next frontier of human life extension. Prev Med. 2012;54:S9–11.
pubmed: 22579241
doi: 10.1016/j.ypmed.2012.03.003
Patronek GJ, Waters DJ, Glickman LT. Comparative longevity of pet dogs and humans: implications for gerontology research. J Gerontol A Biol Sci Med Sci. 1997;52:B171–8.
pubmed: 9158552
doi: 10.1093/gerona/52A.3.B171